These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 15530195)
41. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Ghofrani HA; Grimminger F Eur Respir Rev; 2009 Mar; 18(111):35-41. PubMed ID: 20956121 [TBL] [Abstract][Full Text] [Related]
42. [Pulmonary hypertension. Pathophysiology and current concepts of medication therapy]. Wilkens H Anaesthesist; 2004 Aug; 53(8):734-40. PubMed ID: 15278194 [TBL] [Abstract][Full Text] [Related]
43. [Therapy of pulmonary involvement of rheumatic diseases]. Graninger W Z Rheumatol; 2003 Feb; 62(1):10-5. PubMed ID: 12624797 [TBL] [Abstract][Full Text] [Related]
44. Pulmonary hypertension due to left heart disease. Guazzi M; Borlaug BA Circulation; 2012 Aug; 126(8):975-90. PubMed ID: 22908015 [No Abstract] [Full Text] [Related]
45. Role of endothelins in animal models of hypertension: focus on cardiovascular protection. Moreau P; Schiffrin EL Can J Physiol Pharmacol; 2003 Jun; 81(6):511-21. PubMed ID: 12839263 [TBL] [Abstract][Full Text] [Related]
46. Nitroglycerin therapy in the management of pulmonary hypertensive disorders. Packer M; Halperin JL; Brooks KM; Rothlauf EB; Lee WH Am J Med; 1984 Jun; 76(6A):67-75. PubMed ID: 6430080 [TBL] [Abstract][Full Text] [Related]
47. Modulation and roles of the endothelins in the pathophysiology of pulmonary embolism. Battistini B Can J Physiol Pharmacol; 2003 Jun; 81(6):555-69. PubMed ID: 12839267 [TBL] [Abstract][Full Text] [Related]
48. [Persistent pulmonary hypertension in the newborn infant. Progresses and perspectives]. Lacaze-Masmonteil T; Zupan V; Dehan M Arch Fr Pediatr; 1991 Nov; 48(9):597-601. PubMed ID: 1763927 [No Abstract] [Full Text] [Related]
50. [Acute pulmonary vasodilator testing is a critical step in the management of patients with pulmonary arterial hypertension]. Jiang X; Jing ZC Zhonghua Jie He He Hu Xi Za Zhi; 2008 May; 31(5):378-80. PubMed ID: 18953965 [No Abstract] [Full Text] [Related]
51. [Potential of proteinase-activated receptors as a novel target for treatment of pulmonary hypertension]. Hirano K Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):182-6. PubMed ID: 24717606 [No Abstract] [Full Text] [Related]
52. Insights into Endothelin Receptors in Pulmonary Hypertension. Liu R; Yuan T; Wang R; Gong D; Wang S; Du G; Fang L Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373355 [TBL] [Abstract][Full Text] [Related]
53. Repurposing of the Drug Tezosentan for Cancer Therapy. Ribeiro E; Vale N Curr Issues Mol Biol; 2023 Jun; 45(6):5118-5131. PubMed ID: 37367074 [TBL] [Abstract][Full Text] [Related]
55. Endothelin-1: an interesting peptide or an important mediator in pulmonary diseases? Hay DW Pulm Pharmacol Ther; 1998; 11(2-3):141-6. PubMed ID: 9918746 [No Abstract] [Full Text] [Related]
57. Estrogen paradox in pulmonary hypertension: current controversies and future perspectives. Umar S; Rabinovitch M; Eghbali M Am J Respir Crit Care Med; 2012 Jul; 186(2):125-31. PubMed ID: 22561960 [TBL] [Abstract][Full Text] [Related]
58. Group B Streptococcus, phospholipids and pulmonary hypertension. Curtis J; Kim G; Wehr NB; Levine RL J Perinatol; 2011 Apr; 31 Suppl 1(Suppl 1):S24-8. PubMed ID: 21448200 [TBL] [Abstract][Full Text] [Related]
59. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension. Fitzgerald RK; Oishi P; Ovadia B; Ross GA; Reinhartz O; Johengen MJ; Fineman JR Pediatr Crit Care Med; 2004 Nov; 5(6):571-7. PubMed ID: 15530195 [TBL] [Abstract][Full Text] [Related]